Alpelisib (BYL719)

For research use only.

Catalog No.S2814

109 publications

Alpelisib (BYL719) Chemical Structure

CAS No. 1217486-61-7

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 592 In stock
USD 370 In stock
USD 570 In stock
USD 870 In stock
USD 1270 In stock
USD 1670 In stock
USD 2670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Alpelisib (BYL719) has been cited by 109 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.
Targets
PI3Kα [1]
(Cell-free assay)
5 nM
In vitro

BYL719 inhibits the proliferation of breast cancer cell lines harboring PIK3CA mutations, correlating with inhibition of various downstream signaling components of the PI3K/Akt pathway. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Detroit562 M3rX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;IPHkxNjFvMUCwJO69VQ>? NHfLT2o4OiCq NF3URpNKSzVyPUGuNVAh|ryP NHjrelI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1NFU1QSd-MkW1OVA2PDl:L3G+
SNU-1076 NUjTdXpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TteFAvOS1zMECg{txO NWTiTY9iPzJiaB?= MoexTWM2OD14LkiyJO69VQ>? NUT6T3J{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVA2PDlpPkK1OVUxPTR7PD;hQi=>
SNU-1066 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnCNE4yNTFyMDFOwG0> NGTKVlk4OiCq NHjTSZZKSzVyPUGuNVMh|ryP M{XJbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUWwOVQ6Lz5{NUW1NFU1QTxxYU6=
FaDu M{\QNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKwMlEuOTByIN88US=> M1jD[|czKGh? MYHJR|UxRTF7Lk[2JO69VQ>? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3MEW0PUc,OjV3NUC1OFk9N2F-
SNU1041 M{DNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rOZVAvOS1zMECg{txO NWjNZlBPPzJiaB?= Mn;XTWM2OD1{MD62OUDPxE1? NHTQ[5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1NFU1QSd-MkW1OVA2PDl:L3G+
SCC25 Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrJNE4yNTFyMDFOwG0> NFvoToU4OiCq Mn\hTWM2OD12OT6zNEDPxE1? M{D1WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUWwOVQ6Lz5{NUW1NFU1QTxxYU6=
BON-1 NUjx[mRoTnWwY4Tpc44hSXO|YYm= MUGxM|ExKM7:TR?= MlLBOEBp MX\pcohq[mm2czDQTVNMKCiDS2SgV4VzOzB6KTDhcoQhdVSRUlOxM|Ih[WO2aY\peIlmew>? NXjmPWFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlYzQTJpPkK1NFI3Ojl{PD;hQi=>
QGP-1 Moj2SpVv[3Srb36gRZN{[Xl? M{TGTFEwOTBizszN M37MOVQhcA>? Mlj4bY5pcWKrdIOgVGk{UyBqQVvUJHNmejNyODmgZY5lKG2WT2LDNU8zKGGldHn2bZRq\XN? NX:3Onl7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlYzQTJpPkK1NFI3Ojl{PD;hQi=>
MG-63 NF;Y[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfxR2ZKSzVyPU[g{txO97zOIFnDPVA:OjRizszN NX3YO5J5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE4QTBpPkK0PVYyPzlyPD;hQi=>
HOS NFPvR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvPeXNKSzVyPUG1JO69Ve,:jDDJR|kxRTR{IN88US=> NGHte4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm2NVc6OCd-MkS5OlE4QTB:L3G+
MOS-J MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;tTYNKSzVyPUGwJO69Ve,:jDDJR|kxRTN4IN88US=> NHvwflg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm2NVc6OCd-MkS5OlE4QTB:L3G+
POS-1 NUD1dWN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;VTWM2OD16IN88Ug+9lCCLQ{mwQVM3KM7:TR?= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl4MUe5NEc,OjR7NkG3PVA9N2F-
92.1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe4N4U2ODBvMkCwNEBvVQ>? M3u1UVUh\A>? NUDDeo86cW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4M{W0NEc,OjR3NkO1OFA9N2F-
Mel270 MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f6[lUxOC1{MECwJI5O NYLDVoV6PSCm NF7NXY5qdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWEApW2W{NEezLUB2eCC2bzCxJO69VQ>? NYLhVm9rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlM2PDBpPkK0OVY{PTRyPD;hQi=>
Omm1.3 NWC3ZW5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVm1NFAuOjByMDDuUS=> MmTJOUBl NWflNWk4cW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1? NV;CNVFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlM2PDBpPkK0OVY{PTRyPD;hQi=>
Omm1 NXqycYpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;2dVUxOC1{MECwJI5O NXK4cpV3PSCm M4DkZolvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4M{W0NEc,OjR3NkO1OFA9N2F-
C918 M1eyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[1NFAuOjByMDDuUS=> NFq3Z3Y2KGR? M3XFc4lvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4M{W0NEc,OjR3NkO1OFA9N2F-
Mel290 M{nGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fBRlUxOC1{MECwJI5O M13WOVUh\A>? NHyweJVqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWEApW2W{NEezLUB2eCC2bzCxJO69VQ>? M2TX[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[zOVQxLz5{NEW2N|U1ODxxYU6=
OPM2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\INE42NTJwNTFOwG0> NWK1V4hbPDhiaB?= NIPicWRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3rldVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEC1NVIyLz5{NESwOVEzOTxxYU6=
OPM1 M1zWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfJUYVxOC53LUKuOUDPxE1? MmHvOFghcA>? MYnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MoTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEWxNlEoRjJ2NEC1NVIyRC:jPh?=
U266 NXG1[2M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCwMlUuOi53IN88US=> M3HZclQ5KGh? NFnkcmJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUL5cVk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFUyOjFpPkK0OFA2OTJzPD;hQi=>
MM1R M2PxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTiVWcxNjVvMj61JO69VQ>? NIPmWIE1QCCq NVnEVYo3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHPrRY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwOVEzOSd-MkS0NFUyOjF:L3G+
MM1S M13ZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\aSXMxNjVvMj61JO69VQ>? NEj4eYk1QCCq NWrLUVU5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1LPVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEC1NVIyLz5{NESwOVEzOTxxYU6=
H929 NGi4dXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqwMlUuOi53IN88US=> M3PtSlQ5KGh? MoHybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEWxNlEoRjJ2NEC1NVIyRC:jPh?=
RPMI NUPhfVZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL4fnUxNjVvMj61JO69VQ>? MlfBOFghcA>? NH\4eHFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFThflQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwOVEzOSd-MkS0NFUyOjF:L3G+
SKBR3 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYSz[XdpOzNizszN MlfnOUBl Ml7VbY5pcWKrdIOgN|XwxIViY3XscEBoem:5dHi= NWTBSodrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
MDA453 NWHVSoxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmzN{DPxE1? MoLHOUBl MmrMbY5pcWKrdIOgN|jwxIViY3XscEBoem:5dHi= MoXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
EFM192A Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjuOGs{OyEQvF2= NEXEUnU2KGR? MorPbY5pcWKrdIOgNlfwxIViY3XscEBoem:5dHi= Mon6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
AU565 M{jreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCzN{DPxE1? MnrJOUBl M2DTb4lvcGmkaYTzJFI397zHIHPlcIwh\3Kxd4To NVG5bINHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
MDA361 MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX4TFA{OyEQvF2= NYXDVYJHPSCm MW\pcohq[mm2czC0OQ+9jSClZXzsJIdzd3e2aB?= M1THUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
BT474 M4HCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTJN|Mh|ryP MYO1JIQ> NV:4Npk4cW6qaXLpeJMhOTcxvJWgZ4VtdCCpcn;3eIg> M4DUZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
HCC202 M1[0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfUN|Mh|ryP NYntc3VFPSCm MoHLbY5pcWKrdIOgNlDwxIViY3XscEBoem:5dHi= MknoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
KPL4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj5UVI{OyEQvF2= M4nyRVUh\A>? NHv4[nRqdmirYnn0d{A2QO,:hTDj[YxtKGe{b4f0bC=> M{TtcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
NCL-N87 NWjt[4lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPWflA{OyEQvF2= MojKOUBl MYLpcohq[mm2czCzNg+9jSClZXzsJIdzd3e2aB?= MnTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
UACC812 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnkXHZuOzNizszN M1zv[VUh\A>? NHLmN5hqdmirYnn0d{AzP+,:hTDj[YxtKGe{b4f0bC=> NHzke3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
HCC2218 NU\LbXdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojIN|Mh|ryP NGHufZQ2KGR? MVnpcohq[mm2czCxOg+9jSClZXzsJIdzd3e2aB?= NUTHNmNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
HCC1569 M1rOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDSU|M{OyEQvF2= NIDIe4Y2KGR? NU\iOZR4cW6qaXLpeJMhPe,:hTDj[YxtKGe{b4f0bC=> M4DtOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
OE19 MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrPe|E{OyEQvF2= NID4V|g2KGR? M{nYfIlvcGmkaYTzJFI{97zHIHPlcIwh\3Kxd4To MnjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
OE33 M2\Vbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XX[lM{KM7:TR?= MmrjOUBl M4G0TYlvcGmkaYTzJFI{97zHIHPlcIwh\3Kxd4To MofkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
JIMT1 M{PCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKzPFE{OyEQvF2= MWi1JIQ> NHnzNmNqdmirYnn0d{A697zHIHPlcIwh\3Kxd4To NYLGOmNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
HCC1954 M4f3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPhfmoxOzNizszN MWO1JIQ> M{W5[YlvcGmkaYTzJFI697zHIHPlcIwh\3Kxd4To MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
NUGC4 M2G1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuzN{DPxE1? NVXI[WlqPSCm NFnDbJBqdmirYnn0d{AyPO,:hTDj[YxtKGe{b4f0bC=> NIPUV3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
ZR-75-30 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2qzfFM{KM7:TR?= Mo\BOUBl MVLpcohq[mm2czCtNVXwxIViY3XscEBoem:5dHi= NH3Rc3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
Rat1 MUHQNVEx[WyyaHGgbY5pcWKrdHnvckBie3OjeR?= MojoTWM2OCB;IECuNFc1KM7:TR?= M1[zclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[0NVg6Lz5{NkG2OFE5QTxxYU6=
Rat1 NYjHb4d2WEl|S3HsdIhiKGmwaHnibZRqd25iYYPzZZk> NV72[pF2UUN3MDC9JFAvODd2IN88US=> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJyNkWwOEc,OjZ{ME[1NFQ9N2F-
Rat1 MomzVFEyOGGucHjhJIlvcGmkaYTpc44h[XO|YYm= MUfJR|UxKD1iMD6wO|Qh|ryP NUfWO2xuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NlYxOzRpPkKzO|I3ODN2PD;hQi=>
Rat1 NFfuOlJROTFyZHXseIEhcW6qaXLpeIlwdiCjc4PhfS=> M1fkSWlEPTBiPTCxMlIh|ryP NX\YbFNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOlQyQDlpPkK2NVY1OTh7PD;hQi=>
Rat1 MUfQTVNM\2GvbXGgbY5pcWKrdHnvckBie3OjeR?= M{DKOmlEPTBiPTCxMlIh|ryP NWfkUYxTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFY2ODRpPkK2NlA3PTB2PD;hQi=>
Rat1 NVHJSXZtWDFzMHTlcJRiKGmwaHnibZRqd25iYYPzZZk> NV;D[YxbUUN3MDC9JFEvOiEQvF2= M{jINlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K2NFM1Lz5{M{eyOlA{PDxxYU6=
Rat1 NI\nR4RROTFyYnX0ZUBqdmirYnn0bY9vKGG|c3H5 MoLnTWM2OCB;IEKuNkDPxE1? MlT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNkSxPFkoRjJ4MU[0NVg6RC:jPh?=
Rat1 NWOxUmpGWEl|S3LleIEhcW6qaXLpeIlwdiCjc4PhfS=> NHO5RoNKSzVyIE2gNk4zKM7:TR?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJyNkWwOEc,OjZ{ME[1NFQ9N2F-
Rat1 M2PVWXAyOTCjbIDoZUBqdmirYnn0bY9vKGG|c3H5 MnGyTWM2OCB;IEKuNkDPxE1? M3;xVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K2NFM1Lz5{M{eyOlA{PDxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT(S473) / p-AKT(T308); 

PubMed: 25544637     


PIK3CA hot-spot mutant cell lines were treated with 1 µM BYL719 for the indicated period of time. Lysates were immunoblotted to detect the indicated proteins.

p100β / p110α / p85 / p-ERBB3(Y1289); 

PubMed: 25544637     


BT474 cells were treated with 1 µM BYL719 alone for different durations of time and lysates were immunoprecipitated with ERBB3 antibody. Precipitates were analyzed by western blot with the indicated antibodies.

p-HER2 / IGF-1R; 

PubMed: 25544637     


Cells were treated with 1 μM BYL719 for 24 hr and lysates were immunoblotted to detect the indicated proteins.

pS6 (Ser235-236); 

PubMed: 27048245     


Immunoblots of lysates from parental and resistant cells treated for 24 hours as indicated.

PIM1 / PIM2 / PIM3 / p-PRAS40 / p-RPS6 / p-BAD; 

PubMed: 27604488     


T47D cells cultured to resistance in the presence of BYL719. Both parental (T47D) and resistant (T47DR) cells were treated with BYL719 at 1μM, and cell lysates were prepared at 0, 4, 24 hours for immunoblotting for the indicated proteins.

25544637 27048245 27604488
Growth inhibition assay
Cell viability; 

PubMed: 27602501     


The effect of BYL719 on cellular viability was evaluated in HCT116 (A) and SW480 (B) CRC cells. Briefly, cells were grown, treated with increasing concentrations of BYL719 (5, 10 and 20 μM) and cellular viability determined by MTS assay 72h after treatments. Controls included cells that remained untreated (media ctrl) and vehicle-treated controls (DMSO). Data represent means ± SEM of at least triplicate experiments normalized to controls. All conditions were compared with DMSO. Ctrl, control; DMSO, dimethyl sulfoxide. **, p< 0.01; ***, p< 0.001; ****, p< 0.0001.

27602501
Immunofluorescence
LC3; 

PubMed: 26637440     


SKBR3 GFP-LC3 cells were cultured for 5 days with DMSO, 500 nM BKM120 or 500 nM BYL719. Cells were treated with DMSO or 1 μM Lapatinib for the final 18 h. GFP-LC3 localization was captured by fluorescent microscopy.

26637440
In vivo BYL719(>270 mg/d) shows statistically significant dose-dependent anti-tumor efficacy in PIK3CA mutant xenograft models in rodents. BYL719 has a low clearance, a half-life of 8.5 h and its exposure increases dose proportionally between 30mg/d and 450mg/d, displaying a low inter-individual variability in Cmax and AUC in human. BYL719(270mg/d) shows first signs of clinical efficacy include 1 confirmed partial response in a patient with ER+ breast cancer, and significant PET responses (PMR) and/or tumor shrinkage are achieved in 8 out of 17 evaluated patients. [1]

Protocol

Solubility (25°C)

In vitro DMSO 88 mg/mL (199.33 mM)
Ethanol 2 mg/mL (4.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
4.4 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 441.47
Formula

C19H22F3N5O2S

CAS No. 1217486-61-7
Storage powder
in solvent
Synonyms N/A
Smiles CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04589650 Not yet recruiting Drug: Alpelisib|Drug: Placebo PIK3CA-related Overgrowth Spectrum (PROS) Novartis Pharmaceuticals|Novartis February 2 2021 Phase 2
NCT04544189 Not yet recruiting Drug: Alpelisib|Drug: Fulvestrant|Drug: Placebo Breast Neoplasms Novartis Pharmaceuticals|Novartis December 31 2020 Phase 2
NCT04524000 Recruiting Drug: Alpelisib|Drug: Fulvestrant Advanced Breast Cancer Novartis Pharmaceuticals|Novartis November 20 2020 Phase 2
NCT04300790 Recruiting Drug: Alpelisib|Drug: Metformin|Drug: Fulvestrant Breast Cancer MedSIR|Novartis October 23 2020 Phase 2
NCT04526470 Not yet recruiting Drug: Alpelisib|Drug: Paclitaxel Solid Tumor|Stomach Cancer Seoul National University Bundang Hospital September 1 2020 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Alpelisib (BYL719) | Alpelisib (BYL719) supplier | purchase Alpelisib (BYL719) | Alpelisib (BYL719) cost | Alpelisib (BYL719) manufacturer | order Alpelisib (BYL719) | Alpelisib (BYL719) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID